By IDSE New Staff
The experimental HIV treatment, lenacapavir, achieved high rates of virologic suppression and “meaningful” increases in CD4 counts in patients living with MDR HIV, according to presentations made at CROI 2022.
In the CAPELLA trial, at week 52, 83% (n=30/36) of heavily treatment-experienced participants receiving the investigational long-acting HIV-1 capsid inhibitor, lenacapavir (Gilead), with an optimized background regimen achieved an undetectable viral load